The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

November 1, 2013 • By Jonida Cote, DO, Thomas Harrington, MD, Alicia Meadows, DO, Fan Lin, MD, and Androniki Bili, MD, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Does Anti-Tumor Necrosis Factor-Alpha Increase Cardiovascular Burden?
  • Fellows’ Forum Case Report: Progressive Multifocal Leukoencephalopathy and RA
  • Fellows Forum Case Report: Neuromyelitis Optica
Explore This Issue
November 2013
Fellow’s Forum Case Report
Figure 1: Computed tomography of chest with contrast. Large right peritracheal lymph node measuring 2.4 x 2.7cm.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Sarcoidosis is a multisystem disease of unknown origin characterized by noncaseating granulomas in involved organs. This disease primarily affects the lungs in more than 90% of cases, but extrathoracic manifestations such as cutaneous, lymphatic system, ocular, and liver involvement are commonly present.1 Patients may be asymptomatic at presentation or may have nonspecific symptoms such as fever, malaise, cough, and dyspnea on exertion.1

The diagnosis of sarcoidosis is established when the clinical and radiologic findings are supported by histological evidence of noncaseating epithelioid cell granulomas, once all the other causes of granulomatous conditions have been ruled out.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Although the complete pathophysiology of sarcoidosis is not well understood, it is known that tumor necrosis factor (TNF)–α plays a major role in sarcoidosis development, and TNF-α inhibitors have been used for the treatment of refractory sarcoidosis.3,4 In contrast, a few case reports have described a paradoxical effect, with TNF-α inhibitor therapy leading to the development of granulomatous disease or sarcoidosis.

Here we describe new cases of sarcoidosis in two psoriatic arthritis patients treated with TNF-α inhibitor therapy. The first patient was treated with etanercept and the second with adalimumab.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Transbronchial biopsy of the right upper lung, anterior segment
Figure 2: Transbronchial biopsy of the right upper lung, anterior segment. Pulmonary tissue containing noncaseating epithelioid granulomas (Hematoxylin and Eosin stain x100).

Case #1

A 47-year-old white man with longstanding psoriasis involving mainly his scalp, abdomen, and back and arthritis involving mainly his metacarpophalangeal and proximal interphalangeal joints, wrists, and knees was followed in our rheumatology clinic. He was treated with methotrexate but continued to experience intermittent flares of the rash and arthritis for which he required multiple doses of prednisone or intraarticular corticosteroid injections. Methotrexate was subsequently discontinued due to a persistently elevated serum alkaline phosphatase. Etanercept 50 mg subcutaneously weekly was started in April 2005 and there was marked improvement and remission of both psoriasis and joint disease.

Four years later, the patient developed dyspnea on exertion and a nonproductive cough. Etanercept was discontinued. A chest X-ray (CXR) demonstarted a large right-sided mediastinal mass. Computed tomography (CT) of the chest revealed large subcarinal lymphadenopathy measuring 5.8 x 3 x 2.4 cm and peritracheal lymphadenopathy measuring 2.4 x 2.7 cm (see Figure 1).

A bronchoscopy and fine needle aspiration (FNA) of a mediastinal lymph node yielded tissue showing granulomatous inflammation. Cytology studies were negative for lymphoma. Acid fast bacilli (AFB) and fungal cultures were negative. Purified protein derivative (PPD) skin test was reported as nonreactive. Pulmonary function tests (PFTs) showed decreased vital capacity to 77% of predicted and decreased diffusion lung carbon monoxide capacity (DLCO) to 57% of predicted. Sarcoidosis was felt to be the most likely diagnosis. Etanercept was restarted and the patient was also treated with prednisone. Repeat chest CT imaging one month later showed decreased lymphadenopathy. Upon resolution of respiratory symptoms, prednisone was discontinued.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Psoriatic Arthritis, Sarcoidosis, Therapies, Treatment, Tumor Necrosis Factor–Alpha InhibitorIssue: November 2013

You Might Also Like:
  • Does Anti-Tumor Necrosis Factor-Alpha Increase Cardiovascular Burden?
  • Fellows’ Forum Case Report: Progressive Multifocal Leukoencephalopathy and RA
  • Fellows Forum Case Report: Neuromyelitis Optica
  • EULAR 2014: Non-Tumor Necrosis Factor Biologics Update

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)